Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 4 April 2003:
Vol. 300. no. 5616, p. 33
DOI: 10.1126/science.300.5616.33a
Prev | Table of Contents | Next

News of the Week

DRUG SAFETY:
Conflict-of-Interest Allegations Derail Inquiry Into Antidepressant's 'Dark Side'

Daniel Bachtold

A controversial government review of the safety of antidepressant drugs is in disarray following revelations that some experts involved in the inquiry are shareholders in a company that makes one of the drugs. Last week, the U.K.'s Medicines Control Agency disbanded a panel that had been scrutinizing the track record of selective serotonin reuptake inhibitors, a widely prescribed group of drugs that includes the brands Prozac and Seroxat.

Read the Full Text

ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)